Tuesday, April 25, 2017

Achillion Presents Mixed Trial Results – May, Hep C “Awareness Month”

By Mitchell Young
New Haven: Achillion Pharmaceuticals [Nasdaq: ACHN] presented data on its three drug combination to treat Hepatitis C, at The International Liver Congress in Amsterdam in late April, just a week before the national kick-off of Hep C Awareness Month.
Jansen is financially responsible for all clinical trials and they initiated the Phase II clinical trial, last May of 300 participants of the drug combination, simeprevirodalasvir and AL-335.
Jansen previously developed simeprevir and odalasvir, but required Achilion’s A-335 to achieve the effectiveness needed to cure Hep C.
The clinical results presented could be described as really good and really not so good....
 Continue reading

No comments:

Post a Comment